| Today's Top Story |  |  | | - Celgene's multiple myeloma drug Pomalyst wins FDA approval
The FDA has approved Celgene's Pomalyst, or pomalidomide, as treatment for patients with multiple myeloma who have stopped responding to other therapies. Pomalyst is intended to strengthen the immune system in blocking and eliminating cancer cells. The drug's label will include a warning that it can cause clots and that it should not be used by pregnant women because of the risk for birth defects. HealthDay News (2/8), Reuters (2/8)       | Health Care & Policy | | | | - Guidance for new Alzheimer's treatments unveiled by FDA
The FDA released a nine-page draft guidance document that recommends ways to develop medicines aimed at treating Alzheimer's disease before the onset of brain damage and memory loss. "This draft guidance is intended to serve as a focus for continued discussions between the FDA and pharmaceutical sponsors, the academic community, advocacy groups, and the public," the FDA Center for Drug Evaluation and Research's Dr. Russell Katz said. The Pharmaceutical Research and Manufacturers of America has identified a lack of noninvasive, validated biomarkers and the nature of the illness itself as reasons behind statistics that show only three drugs have been approved since 1998, while 101 candidates have failed. Modern Healthcare (subscription required) (2/7), The Hill/RegWatch blog (2/7), Reuters (2/7) | Company & Financial News | | | | | Food & Agriculture | | | | - Rothamsted considering another biotech wheat trial
Scientists at Rothamsted Research are considering applying for permission to conduct additional field trials of biotech winter wheat. "Feedback we have received from farmers and members of the public has questioned whether it would be better to trial GM winter wheat, because it is more appropriate to this country," a Rothamsted spokesman said. Farmers Weekly Interactive (U.K.) (2/7) | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - RFS offers economic, environmental benefits
 Abandoning or amending the Renewable Fuel Standard would prevent U.S. from realizing its energy, climate and economic goals, and increase its reliance on fossil fuels, write DuPont Industrial Biosciences President Jim Collins and Jeremy Martin of the Union of Concerned Scientists. The RFS is helping to advance the development of cellulosic biofuels, which are a key part of the Union of Concerned Scientists' goal of reducing the country's oil use by half over 20 years. Politico (Washington, D.C.) (2/7)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | The only man I know who behaves sensibly is my tailor; he takes my measurements anew each time he sees me. ... The rest go on with their old measurements and expect me to fit them."
--George Bernard Shaw,
Irish playwright  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, February 08, 2013
- Thursday, February 07, 2013
- Wednesday, February 06, 2013
- Tuesday, February 05, 2013
- Monday, February 04, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment